---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-26-001379"
form_type: "8-K"
ticker: "BGLC"
cik: "0001737523"
company_name: "BioNexus Gene Lab Corp"
filed_at: "2026-03-17T23:59:59+00:00"
generated_at: "2026-05-15T10:33:33.912699+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BioNexus Gene Lab appoints Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics

## Summary
- Dr. Meyyappan appointed CCO of Fidelion effective March 11, 2026; will lead global commercial strategy for VitaGuard MRD platform.
- He brings 15+ years experience in oncology diagnostics, previously at Menarini, Congenica, Variantyx, and QIAGEN.
- BioNexus holds exclusive commercialization rights for VitaGuard in Southeast Asia through its Fidelion investment.
- MRD testing is a fast-growing precision oncology segment for early cancer recurrence detection.

## SEC filing metadata
- accession: 0001477932-26-001379
- form_type: 8-K
- ticker: BGLC
- cik: 0001737523
- company_name: BioNexus Gene Lab Corp
- filed_at: 2026-03-17T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737523/000147793226001379/0001477932-26-001379-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737523/000147793226001379/bglc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-26-001379
- JSON: https://secwatch.observer/filing/0001477932-26-001379.json
- Plain text: https://secwatch.observer/filing/0001477932-26-001379.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.